Literature DB >> 30212441

Notes from the Field: Enterovirus A71 Neurologic Disease in Children - Colorado, 2018.

Kevin Messacar, Alexis Burakoff, W Allan Nix, Shannon Rogers, M Steven Oberste, Susan I Gerber, Emily Spence-Davizon, Rachel Herlihy, Samuel R Dominguez.   

Abstract

Entities:  

Mesh:

Year:  2018        PMID: 30212441      PMCID: PMC6146947          DOI: 10.15585/mmwr.mm6736a5

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


× No keyword cloud information.
On May 10, 2018, the Colorado Department of Public Health and Environment (CDPHE) was notified by Children’s Hospital Colorado (CHCO) of an increase in pediatric cases of meningitis and encephalitis in which patients tested positive for enterovirus (EV). CDPHE surveillance data for May 2018 showed a 2.75-fold increase in encephalitis of unknown etiology compared with the 5-year (May 2013–2017) average; this coincided with a threefold rise in enterovirus/rhinovirus (EV/RV) detections from clinical testing at CHCO during the same period. Specimens from children with neurologic disease were tested by EV reverse transcription–polymerase chain reaction (RT-PCR) at CHCO and VP1 sequencing at CDC (). As of August 26, 2018, EV-A71 was identified in 34 children with neurologic disease. This report describes the clinical, laboratory, and radiologic findings for the first 13 children identified with EV-A71 neurologic disease for whom complete information is available. Patients with EV-A71 central nervous system (CNS) infection had symptom onset during March 10–June 5, 2018; median age was 13 months (range = 10 days–35 months); 11 were male. Twelve had meningitis, nine had encephalitis, and three had acute flaccid myelitis (AFM). All 13 children had fever and irritability; three developed lesions typical of hand, foot, and mouth disease. Neurologic signs included encephalopathy (seven), ataxia (seven), myoclonus (six), limb weakness (four), cranial nerve deficits (two), and seizures (one). Nine of 10 children with a cerebrospinal fluid (CSF) specimen analyzed had a pleocytosis (median white blood cell count = 106 cells/μL, range = 17–698 [normal = 0–5]). Six of eight children who had brain imaging results had abnormalities; five were in the brainstem, three in the cerebellum, and three in the spinal cord. All 13 children had EV-A71 identified in nasopharyngeal, pharyngeal, or rectal specimens. However, only two of 11 children whose CSF was tested had a specimen positive for enterovirus by pan-EV RT-PCR; one of two was available for typing and was identified as EV-A71. All 13 children were hospitalized (median = 5 days; range = 1–23 days), and four required intensive care. The three children who received an AFM diagnosis had residual limb weakness at discharge. All children survived. EV-A71 can cause hand, foot, and mouth disease and neurologic disease, primarily among children aged <5 years (,). Common manifestations include a febrile illness with lesions on the palms, soles, oral mucous membranes, or perineum; and aseptic meningitis. Severe CNS EV-A71 infection can cause brainstem encephalitis leading to cardiopulmonary collapse and polio-like AFM (). EV-A71 epidemics have occurred in the Asian-Pacific region since the late 1990s (). Since the 1980s, the National Enterovirus Surveillance System has detected seasonal endemic EV-A71 activity in the United States; EV-A71 accounts for <1% of typed EVs (). Limited, regional U.S. outbreaks have occurred sporadically in an unpredictable pattern; factors causing year-to-year circulation have not been identified (,). Peak U.S. circulation of EVs, including EV-A71, usually occurs during June–October (,). Although associated with neurologic disease, EV-A71 is uncommonly detected in CSF and is more frequently identified in respiratory and fecal specimens (). In similar EV-A71 outbreaks in Colorado during 2003 and 2005, EV-A71 CNS infection was identified in 16 children (eight in each cluster); 11 children recovered fully, four had residual limb paralysis, and one child died (). At this time, no other clusters of EV-A71 neurologic disease have been reported to CDC in 2018. This investigation highlights the importance of testing nonsterile sites when CNS disease associated with EV is suspected and CSF is negative. Furthermore, health care providers should consider EV-A71 as an etiology when febrile patients display myoclonus, ataxia, or limb weakness. CDPHE has alerted Colorado health care providers to the EV-A71 outbreak and requested reports of EV meningitis and encephalitis, in addition to routine AFM surveillance.
  7 in total

1.  Enterovirus surveillance--United States, 1970-2005.

Authors:  Nino Khetsuriani; Ashley Lamonte-Fowlkes; Steven Oberst; Mark A Pallansch
Journal:  MMWR Surveill Summ       Date:  2006-09-15

2.  Sensitive, seminested PCR amplification of VP1 sequences for direct identification of all enterovirus serotypes from original clinical specimens.

Authors:  W Allan Nix; M Steven Oberste; Mark A Pallansch
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

3.  Neurologic complications in children with enterovirus 71 infection.

Authors:  C C Huang; C C Liu; Y C Chang; C Y Chen; S T Wang; T F Yeh
Journal:  N Engl J Med       Date:  1999-09-23       Impact factor: 91.245

Review 4.  Virology, epidemiology, pathogenesis, and control of enterovirus 71.

Authors:  Tom Solomon; Penny Lewthwaite; David Perera; Mary Jane Cardosa; Peter McMinn; Mong How Ooi
Journal:  Lancet Infect Dis       Date:  2010-10-18       Impact factor: 25.071

5.  Outbreak of neurologic enterovirus type 71 disease: a diagnostic challenge.

Authors:  Carlos M Pérez-Vélez; Marsha S Anderson; Christine C Robinson; Elizabeth J McFarland; W Allan Nix; Mark A Pallansch; M Steven Oberste; Mary P Glodé
Journal:  Clin Infect Dis       Date:  2007-09-13       Impact factor: 9.079

Review 6.  Clinical features, diagnosis, and management of enterovirus 71.

Authors:  Mong How Ooi; See Chang Wong; Penny Lewthwaite; Mary Jane Cardosa; Tom Solomon
Journal:  Lancet Neurol       Date:  2010-11       Impact factor: 44.182

7.  The seasonality of nonpolio enteroviruses in the United States: Patterns and drivers.

Authors:  Margarita Pons-Salort; M Steven Oberste; Mark A Pallansch; Glen R Abedi; Saki Takahashi; Bryan T Grenfell; Nicholas C Grassly
Journal:  Proc Natl Acad Sci U S A       Date:  2018-03-05       Impact factor: 11.205

  7 in total
  10 in total

1.  Clinical Subpopulations in a Sample of North American Children Diagnosed With Acute Flaccid Myelitis, 2012-2016.

Authors:  Matthew J Elrick; Eliza Gordon-Lipkin; Thomas O Crawford; Keith Van Haren; Kevin Messacar; Nicole Thornton; Elizabeth Dee; Annie Voskertchian; Jessica R Nance; Laura S Muñoz; Mark P Gorman; Leslie A Benson; David L Thomas; Carlos A Pardo; Aaron M Milstone; Priya Duggal
Journal:  JAMA Pediatr       Date:  2019-02-01       Impact factor: 16.193

Review 2.  Acute flaccid myelitis: cause, diagnosis, and management.

Authors:  Olwen C Murphy; Kevin Messacar; Leslie Benson; Riley Bove; Jessica L Carpenter; Thomas Crawford; Janet Dean; Roberta DeBiasi; Jay Desai; Matthew J Elrick; Raquel Farias-Moeller; Grace Y Gombolay; Benjamin Greenberg; Matthew Harmelink; Sue Hong; Sarah E Hopkins; Joyce Oleszek; Catherine Otten; Cristina L Sadowsky; Teri L Schreiner; Kiran T Thakur; Keith Van Haren; Carolina M Carballo; Pin Fee Chong; Amary Fall; Vykuntaraju K Gowda; Jelte Helfferich; Ryutaro Kira; Ming Lim; Eduardo L Lopez; Elizabeth M Wells; E Ann Yeh; Carlos A Pardo
Journal:  Lancet       Date:  2020-12-23       Impact factor: 79.321

Review 3.  Recent advances on the role of host factors during non-poliovirus enteroviral infections.

Authors:  Collins Oduor Owino; Justin Jang Hann Chu
Journal:  J Biomed Sci       Date:  2019-06-19       Impact factor: 8.410

4.  A ten-year retrospective evaluation of acute flaccid myelitis at 5 pediatric centers in the United States, 2005-2014.

Authors:  Margaret M Cortese; Anita K Kambhampati; Jennifer E Schuster; Zaid Alhinai; Gary R Nelson; Gloria J Guzman Perez-Carrillo; Arastoo Vossough; Michael A Smit; Robert C McKinstry; Timothy Zinkus; Kevin R Moore; Jeffrey M Rogg; Meghan S Candee; James J Sejvar; Sarah E Hopkins
Journal:  PLoS One       Date:  2020-02-13       Impact factor: 3.240

5.  Structural and functional analysis of protective antibodies targeting the threefold plateau of enterovirus 71.

Authors:  Kuan-Ying A Huang; Daming Zhou; Elizabeth E Fry; Abhay Kotecha; Peng-Nien Huang; Shu-Li Yang; Kuo-Chien Tsao; Yhu-Chering Huang; Tzou-Yien Lin; Jingshan Ren; David I Stuart
Journal:  Nat Commun       Date:  2020-10-16       Impact factor: 14.919

Review 6.  Enterovirus D68 molecular and cellular biology and pathogenesis.

Authors:  Matthew J Elrick; Andrew Pekosz; Priya Duggal
Journal:  J Biol Chem       Date:  2021-01-21       Impact factor: 5.157

7.  Mitigating Future Respiratory Virus Pandemics: New Threats and Approaches to Consider.

Authors:  Gregory C Gray; Emily R Robie; Caleb J Studstill; Charles L Nunn
Journal:  Viruses       Date:  2021-04-08       Impact factor: 5.048

8.  Discovery of Novel Andrographolide Derivatives as Antiviral Inhibitors against Human Enterovirus A71.

Authors:  Jie Kai Tan; Ran Chen; Regina Ching Hua Lee; Feng Li; Kun Dai; Guo-Chun Zhou; Justin Jang Hann Chu
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-18

9.  Emergence of genotype C1 Enterovirus A71 and its link with antigenic variation of virus in Taiwan.

Authors:  Kuan-Ying A Huang; Peng-Nien Huang; Yhu-Chering Huang; Shu-Li Yang; Kuo-Chien Tsao; Cheng-Hsun Chiu; Shin-Ru Shih; Tzou-Yien Lin
Journal:  PLoS Pathog       Date:  2020-09-16       Impact factor: 6.823

10.  Epidemiology of Echovirus 30 Infections Detected in a University Hospital in Catalonia, Spain, in 1995-2020.

Authors:  Margarita Del Cuerpo; Jon Gonzalez de Audicana; Maria Dolores Fernandez-Garcia; Pilar Marín; Montserrat Esteban; Montserrat Español; María Cabrerizo; Núria Rabella
Journal:  Microorganisms       Date:  2022-03-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.